Novaanchora
Nova Anchora develops NvA-021, a topical biologic gel containing genetically corrected Collagen VII for treating Dystrophic Epidermolysis Bullosa (DEB) wounds. This investigative therapeutic is designed for application during routine bandage changes to address existing treatment gaps. The company is advancing its program toward clinical trials, leveraging licensed technology for C7 stability.
Traction –/10
HQ unknown
Updated 5 months ago
Funding
Funding rounds are not available yet.
Founders
Founder details are not available yet.
Product
Features
- Nova Anchora develops NvA-021, a topical biologic gel containing genetically corrected Collagen VII for treating Dystrophic Epidermolysis Bullosa (DEB) wounds. This investigative therapeutic is designed for application during routine bandage changes to address existing treatment gaps. The company is advancing its program toward clinical trials, leveraging licensed technology for C7 stability.